Evidence-gap map · non-drug interventions

Myelodysplastic Syndrome evidence gaps

53 registered non-drug trials, mapped by approach and outcome.

  1. Research Tracker
  2. Evidence-gap maps
  3. Myelodysplastic Syndrome

Which non-drug approaches have been tested for Myelodysplastic Syndrome, and which outcomes they were tested on. An empty cell means no matching trial was found among those searched: a possible gap, not proof that nobody has asked the question.

53registered non-drug trials
6with results posted
16recruiting as of 2026-11-16
44group × outcome cells with at least one trial
⚠️
Research information, not medical advice. These pages index what has been studied in registered trials. A trial existing, completing or posting results says nothing on its own about whether an approach works or is safe for you. Supplements and devices can interact with medicines. Discuss any change with your own clinician.

Evidence-gap matrix

Each number is the count of trials; "with results" is how many of them have posted results on ClinicalTrials.gov. A trial is counted once per group and per outcome domain it covers. The number in brackets after each group is its total trials for this condition.

none1–23–910–2930 or more
Registered non-drug trials for Myelodysplastic Syndrome by intervention group and primary outcome domain
Intervention groupFatigue and energyPost-exertional symptomsCognitionMood, anxiety and wellbeingPainSleepPhysical function and exercise capacityHeart rate, blood pressure and autonomicBreathing and lung functionQuality of lifeWeight and metabolic markersInflammation and other biomarkersSymptom severity and disease activityClinical events, survival and healthcare useFeasibility, adherence and safetyNot classified
Exercise and physical activity (5)···1··4··1····1·
Rehabilitation and therapy services (1)···········1····
Mind-body and psychological approaches (7)1·12211··111·141 with results1
Cognitive training and education (9)···21 with results11 with results·2··2····31 with results2
Diet, fasting and nutrition (1)···1··1··1······
Oxygen, light, temperature and manual therapies (3)··············21 with results1
Supplements and nutraceuticals (22)··1···1····61 with results33471 with results
Care delivery and health services (2)···1··1··1··111·
Other behavioural, not yet classified (8)··12·1···2··2131

The table scrolls sideways: 16 outcome columns.

No trials found for this condition in: Breathing and respiratory training; Sleep and circadian approaches; Neuromodulation and electrical stimulation; Other devices and digital tools.

Where the gaps are

Outcomes not found as a primary outcome in a group's trials

  • Among the 9 trials of cognitive training and education found, none used inflammation and other biomarkers as a primary outcome (8 trials of other approaches did).
  • Among the 22 trials of supplements and nutraceuticals found, none used mood, anxiety and wellbeing as a primary outcome (6 trials of other approaches did).
  • Among the 9 trials of cognitive training and education found, none used symptom severity and disease activity as a primary outcome (6 trials of other approaches did).
  • Among the 9 trials of cognitive training and education found, none used clinical events, survival and healthcare use as a primary outcome (6 trials of other approaches did).
  • Among the 22 trials of supplements and nutraceuticals found, none used quality of life as a primary outcome (5 trials of other approaches did).
  • Among the 22 trials of supplements and nutraceuticals found, none used pain as a primary outcome (3 trials of other approaches did).
  • Among the 9 trials of cognitive training and education found, none used cognition as a primary outcome (3 trials of other approaches did).

Questions studied but with no results posted

  • Exercise and physical activity × physical function and exercise capacity: 4 trials registered, none with results posted (1 still recruiting)
  • Supplements and nutraceuticals × feasibility, adherence and safety: 4 trials registered, none with results posted (2 still recruiting)
  • Supplements and nutraceuticals × symptom severity and disease activity: 3 trials registered, none with results posted (1 still recruiting)
  • Supplements and nutraceuticals × clinical events, survival and healthcare use: 3 trials registered, none with results posted (3 still recruiting)

Design a trial with DecenTrial (beta) Fund a component of this work

A gap here means no matching trial was found among those searched, not that an approach would work. About one trial in six has primary outcomes the rules cannot classify, so a few gaps may be measured under another name. Some gaps are gaps for good reason.

Most-studied approaches for Myelodysplastic Syndrome

Download this matrix (CSV) Non-drug evidence map Evidence brief RepurpOS condition page Condition page

How outcomes are grouped

Each trial's primary outcome measures are sorted into domains by keyword rules. 11 trials for this condition have primary outcomes the rules could not classify; they appear in the last column rather than being dropped. Checked against 90 hand-labelled outcomes; on a held-out sample of 30, the rules agreed with the hand label for 20 before adjustment, and every outcome they labelled was labelled correctly (misses were left unclassified).

Trial selection and exclusions follow the non-drug evidence map method. Source: ClinicalTrials.gov, searched 2026-11-16.